[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-transplant":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,46,70,101,126,153,187,210,242,262,289,314,339,374,398],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100548836","effect-of-resistance-training-in-patients-on-the-waiting-list-for-heart-transplant-100548836",false,"NCT06426173","Effect of Resistance Training in Patients on the Waiting List for Heart Transplant","Effect of Resistance Training on Functional Capacity, Quality of Life and Cardiac Biomarkers in Patients on the Waiting List for Heart Transplant: a Randomized and Controlled Clinical Trial","Inclusion Criteria:\n\n* patients included in heart transplant list ≤1 month\n* hemodynamically stable in the last 48 hours defined as mean arterial pressure (MAP) ≥ 60 mmHg and ≤ 120 mmHg and - Heart rate (HR) ≥ 60 bpm and ≤ 120 mmHg.\n* dobutamine dose ≤ 10 mcg\u002Fkg\u002Fmin\n\nExclusion Criteria:\n\n* heart failure of arrhythmogenic and\u002For restrictive etiology\n* presence of uncontrolled acute arrhythmias\n* cognitive, orthopedic, or neuromotor changes that prevent functional tests from being carried out","ALL","18 Years","70 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The present longitudinal, randomized, and blinded clinical trial aims to:\n\n* Evaluate the effects of resistance training on the functional capacity, quality of life, and cardiac biomarkers of hospitalized patients with heart failure (HF) on the waiting list for heart transplantation (HTx).\n* Evaluate the associations between Fried's frailty classification and functional capacity responses to resistance training.\n\nThe protocol will have a total duration of 12 weeks.",[27,28],"Heart Failure","Heart Transplant",[30,31,32],"heart failure","resistance training","cardiac rehabilitation","RECRUITING","2026-06-18",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":37},"2024-06-18",{"date":41,"type":21},"2027-06-30",{"name":43,"class":44},"University of Sao Paulo General Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100421608","phase-3-aerial-trial-antiplatelet-therapy-in-heart-transplantation-100421608","NCT04770012","AERIAL Trial: Antiplatelet Therapy in Heart Transplantation","Early Initiation of Antiplatelet ThERapy In HeArt TranspLantation: AERIAL Trial","Inclusion Criteria:\n\n1. Heart transplant\n2. Age ≥18 years\n3. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Allergy or known intolerance to aspirin\n2. Allergy or known intolerance to clopidogrel\n3. Intracranial hemorrhage ≤14 days\n4. Bleeding disorder\n5. Platelet count \\\u003C50 x 109\u002FL\n6. History of aspirin related gastrointestinal bleeding or ulcers\n7. Non-cardiac indication for antiplatelet therapy\n8. Anticoagulation \\>3 months\n9. Allergy to iodinated contrast\n10. Unable to undergo coronary angiography due to glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2 for non-dialysis patients\n11. Unable to undergo coronary angiography due to unsuitable vascular access\n12. Combined solid organ transplantation.",{"count":54,"type":21},135,[56],"PHASE3","Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.",[59,28],"Cardiac Allograft Vasculopathy","2026-04-29",{"date":62,"type":37},"2026-05-06",{"date":64,"type":37},"2021-06-28",{"date":66,"type":21},"2029-03",{"name":68,"class":44},"Ottawa Heart Institute Research Corporation",3,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100552817","phase-2-belatacept-in-heart-transplantation-100552817","NCT06478017","Belatacept in Heart Transplantation","Belatacept With Delayed Tacrolimus Withdrawal Versus Standard-of-Care Tacrolimus in Heart Transplant Recipients (RTB-013)","Inclusion Criteria:\n\nStudy entry\n\n1. Subject must be able to understand the purpose of the study and be willing to participate and provide written consent\n2. Recipient of a primary heart transplant (heart transplant only)\n3. Epstein-Barr Virus (EBV) seropositive (VCA IgG, EBNA IgG). If EBNA is not available, enrollment may proceed but the result must be available prior to randomization.\n4. Agreement to use contraception; according to the Food and Drug Administration (FDA) Office of Women's Health (http:\u002F\u002Fwww.fda.gov\u002Fbirthcontrol), there are a number of birth control methods that are more than 80% effective. Female participants of child-bearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for the duration of the study\n5. In the absence of a contraindication, vaccinations must be up to date per the Division of Allergy, Immunology, and Transplantation (DAIT) Vaccination Guidance for Patients in Transplant Trials (niaidtransplantstudies.org)\n6. Mechanical support or investigational drug trials where the intervention ends at the time of transplantation are permitted.\n\nRandomization\n\n1. Recipient of a primary heart transplant\n2. No desensitization therapy prior to transplant\n3. Negative crossmatch actual or virtual, on the most recent sera as determined by the participating study center\n4. Female subjects of childbearing potential must have a negative pregnancy test (serum or urine) prior to randomization\n5. Agreement to use contraception; according to the FDA Office of Women's Health (http:\u002F\u002Fwww.fda.gov\u002Fbirthcontrol), there are a number of birth control methods that are more than 80% effective. Female participants of child-bearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for the duration of the study. Those who choose oral contraception must agree to use a second form of contraception after administration of study drug for a period of 1 year after the last dose of study drug\n6. Pre-transplant eGFR (CKD-epi) \\>30ml\u002Fmin\u002F1.73m\\^2. If eGFR \\\u003C30ml\u002Fmin\u002F1.73m\\^2 at the time of randomization, participation is permitted if the study physician determines that renal recovery is expected. Participants who are on dialysis at randomization or are expected to require dialysis at or after randomization will not be permitted to participate.\n\nExclusion Criteria:\n\nStudy entry\n\n1. Candidate for multiple solid organ or tissue transplants\n2. Prior history of any organ, tissue, or cellular transplant\n3. Currently breast-feeding a child or plans to become pregnant during the timeframe of the study follow up period\n4. History of severe allergic and\u002For anaphylactic reactions to humanized or murine monoclonal antibodies\n5. Known hypersensitivity to NULOIX (belatacept) or ORENCIA (Abatacept)\n6. Previous treatment with NULOIX (belatacept) or ORENCIA (Abatacept)\n7. Epstein Barr Virus (EBV) seronegative or indeterminant\n8. Human Immunodeficiency Virus (HIV) positive\n9. Hepatitis B surface antigen positive\n10. Hepatitis B core antibody positive\n11. Hepatitis C virus antibody (HCV Ab+) and hepatitis C virus (HCV) Polymerase Chain Reaction (PCR) positive patients\n12. Patients with active Tuberculosis (TB) in the past 2 years, whether or not it was adequately treated; patients with documented treatment of active TB greater than 2 years ago will be allowed to participate if there is documentation of adequate treatment according to locally accepted clinical practice\n13. Subjects must be tested for latent TB infection (LTBI) within a year prior to transplant. Testing should be conducted using either a PPD or Interferon-gamma release assay (i.e., QuantiFERON-TB, T-SPOT.TB). Patients with a positive test for latent TB infection (LTBI) must have completed appropriate therapy for LTBI (https:\u002F\u002Fwww.cdc.gov\u002Ftb\u002Ftopic\u002Ftreatment\u002Fltbi.htm). A subject is considered eligible only if they have a negative test for LTBI within one year prior to transplant OR if they have completed appropriate LTBI therapy within one year prior to transplant\n14. Positive serology for T. cruzi or known\u002Fsuspected history of Chagas disease\n15. Participants currently or formerly residing in regions of the US that are highly endemic for coccidiomycosis will undergo serological testing, as per the site's standard of care. Participants with positive serology who have previously been fully treated, will be permitted to participate pending full treatment, and then require prophylaxis as further outlined in Section 7 for the duration of the study. Participants with negative serology who reside in regions where coccidiomycosis is endemic are eligible for enrollment only if they receive prophylaxis for the duration of the study. Endemic regions are determined by site based on local standard of care\n16. Findings on pre-transplant or pre-randomization chest x-ray or CT scan suggestive of fungal infection where an alternative etiology is not identified. Participants with a history of positive serologies for histoplasmosis or blastomycosis, performed for clinical indications will be permitted to participate if they have a normal chest x-ray or CT scan but require prophylaxis\n17. Known active current viral, fungal, mycobacterial or other infections (including, but not limited to atypical mycobacterial disease and herpes zoster), not including drive line infections\n18. Current white blood cell (WBC) count \\\u003C3.0 or an absolute neutrophil count (ANC) of less than 1500 cells\u002Fmm\\^3 or recurrent leukopenia that is likely to necessitate immunosuppression reduction after transplant, as determined by the site PI\n19. History of active inflammatory bowel disease, chronic diarrhea, or malabsorption\n20. History of malignancy, per discretion of oncology consult and study oversight team, will be permitted to participate\n21. History of AL amyloidosis\n22. Patients who are administered or intended to be administered induction therapy (cytolytic agents such as anti-thymocyte globulin or anti-IL2R therapies such as basiliximab) in the immediate peri-transplant period\n23. Patients who i) have undergone desensitization, ii) are undergoing or are planned to undergo desensitization, or iii) are intended to receive therapeutic interventions that are used for the purpose of desensitization prior to transplant\n24. Pretransplant Calculated Panel Reactive Antibody (cPRA) \\> 50% as defined by local site practices\n25. The use of immunosuppressive biologics within 1 month prior to transplant is not permitted. Non-immunosuppressive biologics such as proprotein convertase subtilisin\u002Fkexin type 9 (PCSK9) inhibitors must be stopped at the time of transplant\n26. Patients for whom there is an intent to administer biologics other than those indicated by protocol during the study period\n27. The intended use of high dose (\\>= 2g\u002Fkg) intravenous immunoglobulin before or at the time of transplant or before study drug administration\n28. A personal history of severe hypogammaglobulinemia (\\\u003C300mg\u002FdL)\n29. Intent to give the patient a live vaccine within 30 days prior to randomization\n30. Use or intended use of other investigational drugs after transplant\n31. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the potential participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study\n\nRandomization\n\n1. Recipient of multiple solid organ or tissue transplants\n2. Prior history of any organ, tissue, or cellular transplant\n3. Currently breast-feeding a child or plans to become pregnant during the timeframe of the study follow up period\n4. History of severe allergic anaphylactic reactions to humanized or murine monoclonal antibodies\n5. Known hypersensitivity to Belatacept (NULOJIX) or Abatacept (ORENCIA)\n6. Previous treatment with Belatacept (NULOJIX) or Abatacept (ORENCIA)\n7. Epstein Barr Virus (EBV) seronegative or indeterminant (recipient must be seropositive for VCA IgG and EBNA IgG)\n8. HIV positive patient\n9. Hepatitis B surface antigen positive patient\n10. Hepatitis B core antibody positive patient\n11. Hepatitis B negative transplant recipient that received a transplant from a Hepatitis B core antibody positive donor\n12. Hepatitis C virus antibody (HCV Ab+) and HCV PCR positive patients\n13. Recipient of allograft from a hepatitis C virus nucleic acid test (NAT) positive donor\n14. Patients with a previous history of active Tuberculosis (TB) in the past 2 years, whether or not it was adequately treated; patients with documented treatment of active TB greater than 2 years ago will be allowed to participate if there is documentation of adequate treatment according to locally accepted clinical practice\n15. Subjects must be tested for latent TB infection (LTBI) within a year prior to transplant. Testing should be conducted using either a PPD or Interferon-gamma release assay (i.e., QuantiFERON-TB, T-SPOT.TB). Patients with a positive test for latent TB infection (LTBI) must complete appropriate therapy for LTBI (https:\u002F\u002Fwww.cdc.gov\u002Ftb\u002Ftopic\u002Ftreatment\u002Fltbi.htm). A subject is considered eligible only if they have a negative test for LTBI within one year prior to transplant OR if they have completed appropriate LTBI therapy within one year prior to transplant\n16. Positive serology for T. cruzi or known\u002Fsuspected history of Chagas disease\n17. Participants currently or formerly residing in regions of the US that are highly endemic for coccidiomycosis will undergo serological testing, as per the site's standard of care. Participants with positive serology who have previously been fully treated, will be permitted to participate but require prophylaxis as further outlined in Section 7 of the protocol for the duration of the study. Participants with negative serology who reside in regions where coccidiomycosis is endemic are eligible for enrollment only if they receive prophylaxis for the duration of the study. Endemic regions are determined by site based on local standard of care\n18. Findings on pre-transplant or pre-randomization chest x-ray or CT scan suggestive of fungal infection where an alternative etiology is not identified. Participants with a history of positive serologies for histoplasmosis or blastomycosis, performed for clinical indications, will be permitted to participate if they have a normal chest x-ray or CT scan but require prophylaxis as further outlined in Section 7 of the protocol\n19. Known active current viral, fungal, mycobacterial or other infections (including, but not limited to atypical mycobacterial disease and herpes zoster), not including drive line infections\n20. Current white blood cell (WBC) count \\\u003C3.0 or an absolute neutrophil count (ANC) of less than 1500 cells\u002Fmm\\^3 or recurrent leukopenia that is likely to necessitate immunosuppression reduction after transplant, as determined by the site PI\n21. CMV high risk mismatch (D+\u002FR-)\n22. History of active inflammatory bowel disease, chronic diarrhea, or malabsorption\n23. History of malignancy, per discretion of oncology consult and study oversight team, will be permitted to participate\n24. History of AL amyloidosis\n25. Patients who are administered or intended to be administered induction therapy (cytolytic agents such as anti-thymocyte globulin or anti-IL2R therapies such as basiliximab) in the immediate peri-transplant period\n26. Patients who have undergone desensitization or received therapeutic interventions that are used for the purpose of desensitization prior to transplant\n27. cPRA \\> 50% at the time of transplant or any donor specific antibodies before or at the time of transplant as determined by local site practices\n28. Patients who have been treated with immunosuppressive biologics within 1 month prior to transplant (non-immunosuppressive biologics must have been stopped at the time of transplant)\n29. Patients for whom there is an intent to administer biologics other than those indicated by protocol during the study period\n30. Patients who are administered or intended to be administered high dose (\\>=2g\u002Fkg) intravenous immunoglobulin in the immediate post-transplant period\n31. A personal history of severe hypogammaglobulinemia (\\\u003C300mg\u002FdL)\n32. Receipt of a live vaccine within 30 days prior to randomization\n33. Intent to use any other investigational drugs after transplantation\n34. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study","71 Years",{"count":79,"type":21},66,[81],"PHASE2","This is a phase 2, prospective, multi-center, open-label clinical trial. Sixty-six (66) primary heart transplant recipients will be randomized (1:2) to receive either standard-of-care, tacrolimus-based immunosuppression, or a belatacept-based regimen with gradual tacrolimus withdrawal over 9-months post-transplant. Both study arms will receive CellCept® (mycophenolate mofetil- MMF) or Myfortic® (mycophenolate sodium). Corticosteroids will be continued throughout the study in the belatacept arm.\n\nThe primary objective is to evaluate whether NULOJIX® (belatacept), when implemented with gradual tacrolimus withdrawal over 9 months, is safe with respect to preventing the composite endpoint of acute cellular rejection (ACR) \\>= International Society of Heart and Lung Transplantation (ISHLT) 2R, hemodynamic compromise rejection in the absence of a biopsy or histological rejection, re-transplantation, and death at 18 months post-transplant.",[28],[85,86,87,88,89],"Heart transplant","Transplantation","Standard of care","Belatacept","Tacrolimus","2026-04-01",{"date":92,"type":37},"2026-04-07",{"date":94,"type":37},"2025-01-29",{"date":96,"type":21},"2028-01-31",{"name":98,"class":99},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",5,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":125},"100584877","xvivo-heart-box-xhb-with-supplemented-xvivo-heart-solution-sxhs-continued-access-protocol-cap-100584877","NCT06895070","XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)","PRESERVE CAP: A Prospective, Multi-Center, Single-Arm, Open-Label Study of Hearts Transplanted After Non-Ischemic Heart Preservation From Extended Donors Continued Access Protocol","NIHP-CAP-001","Inclusion Criteria Recipient:\n\nTo be eligible to participate in this study, a recipient must meet all the following criteria:\n\n1. Age ³18 years.\n2. Signed informed consent form (ICF).\n3. Listed for heart transplantation.\n\nExclusion Criteria Recipient:\n\n1. Previous solid organ or bone marrow transplantation.\n2. Requires a multi-organ transplant.\n3. Subject is enrolled and ongoing in another investigational pharmaceutical or medical device clinical trial (Exception: observational studies are permitted).\n4. Subject is on mechanical circulatory support pre-transplant other than durable LVAD, Impella or intra-aortic balloon pump (IABP).\n5. History of complex congenital heart disease ie: single ventricle physiology (per Investigator's discretion and XVIVO review).\n6. Subject on renal replacement therapy\u002Fdialysis.\n7. Ventilator dependence (subject is intubated at time of transplant\u002Funable to provide consent or re-affirmation of consent).\n8. Sensitized participants meeting any of the following:\n\n   * Participant with calculated Panel Reactive Antibody (cPRA) greater than 50%\n   * Participant undergoing any desensitization treatment (also with cPRA less than 50%)\n   * Participant with a positive prospective crossmatch and\u002For a positive virtual cross match\n\nDonor Inclusion Criteria:\n\nTo be eligible to participate in this study, the donor heart must meet the following criteria:\n\n1. Estimated Cross Clamp Time ≥4 hours OR\n2. Estimated Cross Clamp ≥ 2 hours AND\n\nAny one or more of the following:\n\n* Age ≥50 years\n* LVEF 40% - 50% at time of provisional acceptance. (Refer to section 6.3.4 for definition of provisional acceptance).\n* Down-time ≥20 minutes\n* Hypertrophy septal thickness \\>12 - ≤16mm\n* Angiographic luminal irregularities with no significant CAD OR 1) Donation after Circulatory Death (DCD)\n\nDonor Exclusion Criteria:\n\nDonor hearts that meet any of the following criteria will be excluded from transplantation in this study:\n\n1. Unstable hemodynamics requiring high-dose inotropic support.\n2. Significantly abnormal coronary angiogram defined as CAD \\> 50% stenosis of one or more vessels or if the donor heart exhibits any contusions, structural damage, gross abnormalities, or palpable CAD on final examination.\n3. Moderate to severe cardiac valve pathology.\n4. Investigator's clinical decision to exclude from trial.\n5. Previous sternotomy.",{"count":110,"type":21},60,[24],"The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.",[28,27,114],"Transplant; Failure, Heart","2026-03-16",{"date":117,"type":37},"2026-03-18",{"date":119,"type":37},"2025-07-10",{"date":121,"type":21},"2031-05",{"name":123,"class":124},"XVIVO Perfusion","INDUSTRY",14,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100629166","phase-3-switch-apixaban-vs-vitamin-k-in-hm3-100629166","NCT07471139","SWITCH: Apixaban vs Vitamin K in HM3","The SWITCH Trial: A Randomized Controlled Study of Apixaban Versus Vitamin K Antagonists in Patients With HeartMate 3 Left Ventricular Assist Devices","Inclusion Criteria:\n\n* Participants will have HeartMate3 LVAD implanted \\> 3 months before enrollment\n* ≥ 18 years old\n* Treated with WARFARIN SODIUM\n* Participant must provide written informed consent prior to any clinical investigation related procedure\n* In female participants of childbearing capability, not currently pregnant and on appropriate contraception\n\nExclusion Criteria:\n\n* Participation in any other clinical investigation(s) involving a Mechanical Circulatory Support (MCS) device, or interventional investigation(s) likely to confound study results or affect study outcome\n* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results\n* Known allergy to Apixaban\n* Bridge to transplant\n* Severe renal dysfunction Estimated Glomerular Filtration Rate (eGFR) \\\u003C20\n* History of major bleeding event with subsequent reduction of INR goal to \\\u003C 1.8\n* Apixaban dose reduction criteria (Age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg\u002FdL)\n* Aortic root thrombus","80 Years",{"count":135,"type":21},460,[56],"This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.",[139,27,140,141,142,28],"LVAD (Left Ventricular Assist Device) Thrombosis","Bleeding","Thrombosis; Artery","Stroke","NOT_YET_RECRUITING","2026-03-11",{"date":146,"type":37},"2026-03-13",{"date":148,"type":21},"2026-06",{"date":150,"type":21},"2029-06",{"name":152,"class":44},"Columbia University",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":186},"100564123","phase-4-randomized-trial-of-sglt2i-in-heart-transplant-recipients-100564123","NCT06625073","Randomized Trial of SGLT2i in Heart Transplant Recipients","Randomized Trial of Sodium-glucose Cotransporter 2 Inhibition in Heart Transplant Recipients","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Heart transplant recipient, 3 months after transplant\n\nExclusion Criteria:\n\n1. eGFR \\\u003C20 mL\u002Fmin\u002F1.73m2\n2. Type 1 diabetes mellitus\n3. HbA1C \\>10%\n4. Baseline UACR \\\u003C30 mg\u002Fg in patients without T2D\n5. Known allergy or intolerance to SGLT2i\n6. Active uncontrolled infection\n7. Multiorgan transplant\n8. SGLT2i treatment in the last 30 days\n9. Pregnancy, breast-feeding or woman of child-bearing age not on birth control",{"count":161,"type":21},200,[163],"PHASE4","Heart transplant (HTx) is an established therapy for advanced heart disease that restores quality of life and improves survival. However, due to preexisting comorbidities combined with the immunosuppressive therapies required after transplantation, HTx recipients remain at high risk for kidney, cardiovascular (CV), and metabolic disease. Large randomized clinical trials have recently shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) have potent kidney protective and CV benefits in many populations of patients with chronic kidney disease (CKD), CV disease and\u002For diabetes. SGLT2i have not been studied prospectively in HTx recipients, which represents a barrier to their use in this population.\n\nIn this multicenter randomized controlled trial in Veterans with HTx, investigators will evaluate the potential benefits of empagliflozin on kidney function, cardiometabolic risk, erythropoiesis, and functional status. A total of 200 Veterans will be randomly assigned to receive either empagliflozin 10 mg daily or a matching placebo for 12 months.",[28,166,167],"Cardiovascular Disease","Kidney Disease",[28,169,170,171,172,173,174,175],"Empagliflozin","Safety and Tolerability","Kidney Outcomes","Cardiometabolic Outcomes","Erythropoiesis","Functional Status","Quality of Life","2026-01-21",{"date":178,"type":37},"2026-01-22",{"date":180,"type":37},"2026-01-20",{"date":182,"type":21},"2030-02-28",{"name":184,"class":185},"VA Office of Research and Development","FED",6,{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100604130","enhancing-heart-allograft-function-with-the-ocs-heart-system-trial-100604130","NCT07145515","Enhancing Heart Allograft Function With the OCS Heart System Trial","Enhancing Heart Allograft Function With the OCS Heart System (ENHANCE) Trial","ENHANCE","Part A - DCD Donor Hearts \\& DBD Donor Hearts Initially Deemed Unsuitable for Cold Storage (Current Approved Indications):\n\nDonor Inclusion Criteria\n\n* Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and\u002For on the back table in the donor operating room.\n* All DCD donors eligible for functional warm ischemic time criteria ≤ 30 minutes. WIT defined as time from when mean systolic blood pressure (SBP) is \\\u003C50mmHg (sustained for at least 5 minutes) to aortic cross clamp and administration of old cardioplegia in the donor.\n* DBD donor hearts with an expected cross clamp of ≥ 4 hours\n* DBD donor hearts with any of the following organ quality concerns, regardless of cross clamp time:\n\n  * Donor age ≥ 40 years old\n  * Unknown downtime\n  * Insignificant CAD\n  * LVEF ≤ 50%\n\nDonor Exclusion • Moderate to severe aortic incompetence\n\nPart B - DBD Donor Hearts Currently Used with Cold Storage (New Indication):\n\nDonor Inclusion Criteria\n\n* Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and\u002For on the back table in the donor operating room.\n* Eligible for randomization to OCS or SCS treatment arms.\n* DBD donor hearts with an expected cross clamp time of \\\u003C 4 hours.\n\nDonor Exclusion\n\n* Moderate to severe aortic incompetence\n* DBD donor with any of the following organ quality concerns:\n\n  * Donor age ≥ 40 years old\n  * Unknown downtime\n  * Insignificant CAD\n  * LVEF ≤ 50%\n\nRecipient Eligibility Criteria (for Part A and B Cohorts)\n\nInclusion\n\n* Signed informed consent document and authorization to use and disclose protected health information\n* Heart transplant candidate\n* Age ≥ 18 years old\n\nExclusion\n\n• Participant in any other interventional clinical or investigational trials\u002Fprograms that may confound the outcomes of this trial",{"count":196,"type":21},655,[24],"This trial is designed to evaluate the safety and effectiveness of the novel OCS Solution and OCS Functional Enhancer (OFE) to support FDA approval in both DBD and DCD heart transplantation. In addition, this trial will evaluate the performance of the novel OCS Solution and OFE compared to Static Cold Storage (SCS) in DBD heart transplantation to potentially demonstrate superiority.",[28],"2026-01-08",{"date":202,"type":37},"2026-01-12",{"date":204,"type":21},"2026-01",{"date":206,"type":21},"2027-07-30",{"name":208,"class":124},"TransMedics",8,{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":222,"phases":4,"briefSummary":223,"conditions":224,"keywords":228,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":45},"100441240","fitness-and-lung-function-among-survivors-of-heart-transplant-leukemia-and-infant-bpd-through-exercise-100441240","NCT05025774","Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise","Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant Bronchopulmonary Dysplasia (BPD, Also Known as Chronic Lung Disease of Prematurity) Through Exercise (FLASHLITE)","FLASHLITE","Inclusion Criteria:\n\n* Cases:\n\n  * Acute lymphoblastic leukemia survivor, OR living with chronic lung disease of prematurity, OR living with heart transplant\n  * 8-25 years old\n  * Height: ≥ 48 inches\n  * Ambulatory without assistance\n  * English speaking\n  * Normotensive (\\\u003C95th percentile for age; okay if managed with antihypertensive medication)\n  * SpO2 \\>92%\n  * Not pregnant\n  * ALL survivor specific: must have completed therapy ≥ 3 months prior to study entry\n* Controls\n\n  * 8-25 years old\n  * Height: ≥ 48 inches\n  * Ambulatory without assistance\n  * English speaking\n  * No history of arrhythmia or known cardiac dysfunction at baseline\n  * Normotensive (\\\u003C95th percentile for age; okay if managed with antihypertensive medication)\n  * SpO2 \\>95%\n  * Not pregnant\n\nExclusion Criteria:\n\n* Cases:\n\n  * ALL specific: received cranial radiation, bone marrow transplant recipients\n  * Investigator or patient's primary physician deems the patient unsuitable for the study\n* Controls:\n\n  * History of malignancy, CLD or HT or any other diagnosis which may reduce cardiorespiratory function\n  * Investigator deems the patient unsuitable for the study","8 Years","25 Years",{"count":221,"type":21},90,"OBSERVATIONAL","This study aims to more accurately assess cardiac function, ventilation and exercise capacity in a non-invasive fashion, and to better characterize exercise intolerance in the setting of three populations of individuals with chronic diseases of childhood (acute lymphoblastic leukemia (ALL), chronic lung disease (CLD) of prematurity, and post-heart transplant (HT))",[225,226,227,28],"Chronic Lung Disease","Chronic Obstructive Pulmonary Disease","Acute Lymphoblastic Leukemia",[229,230,231,232],"Quality of life","Lung function","Fitness","Exercise","2025-11-21",{"date":235,"type":37},"2025-11-24",{"date":237,"type":37},"2025-03-14",{"date":239,"type":21},"2026-12-01",{"name":241,"class":44},"Masonic Cancer Center, University of Minnesota",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":248,"targetDuration":250,"studyType":222,"phases":4,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":261},"100509582","us-national-ocs-heart-perfusion-ohp-registry-100509582","NCT05915299","US National OCS Heart Perfusion (OHP) Registry","Inclusion Criteria:\n\n* N\u002FA\n\nExclusion Criteria:\n\n* N\u002FA",{"count":249,"type":21},100000,"5 Years","This Registry is a sponsor initiated, multi-center, observational post-approval registry with independent academic oversight.",[28],"2025-10-29",{"date":255,"type":37},"2025-10-30",{"date":257,"type":37},"2023-08-25",{"date":259,"type":21},"2033-08-31",{"name":208,"class":124},37,{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":278,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":100},"100510949","mcnair-study-comparative-effectiveness-of-in-person-and-telehealth-cardiac-rehabilitation-100510949","NCT05933083","MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation","Inclusion Criteria:\n\n1. Age 18 or older\n2. Eligible for cardiac rehabilitation\n\n   1. Diagnosis within 1 year prior to consent\n\n      * Myocardial infarction\n      * Percutaneous coronary intervention\n      * Coronary artery bypass\n      * Heart valve repair or replacement\n      * Heart transplant\n   2. Chronic stable angina, or\n   3. Chronic systolic heart failure (ejection fraction ≤ 35%)\n   4. Referred to cardiac rehabilitation by a doctor or advanced practice provider for another indication that is covered by the participant's insurance, such as heart failure with preserved ejection fraction or aortic surgery.\n3. Willing to be randomized to in-person or telehealth cardiac rehabilitation\n4. Able to communicate in English or Spanish\n\nExclusion Criteria:\n\n1. Unstable arrhythmias which may make unmonitored exercise unsafe (e.g., history of ventricular tachycardia not on medical therapy and without an implantable cardioverter defibrillator)\n2. Unsafe for patient to participate in the opinion of the investigator\n3. Hospice\n4. Unable to consent for self",{"count":269,"type":21},516,[24],"Cardiac rehabilitation is a medically recommended program for patients with certain heart conditions. It includes exercise training, health education, and counseling. Unfortunately, many patients do not participate in cardiac rehabilitation. Some find it challenging to attend the in-person sessions. This study aims to compare two methods of delivering cardiac rehabilitation: in-person and through telehealth. The investigators want to know if the effects of these two programs are alike and if certain individuals benefit more from one program over the other.",[273,274,275,276,277,28],"Myocardial Infarction","Heart Failure, Systolic","Heart Valve Diseases","Angina, Stable","Coronary Artery Disease",[279],"cardiac rehabilitation, telehealth","2025-09-09",{"date":282,"type":37},"2025-09-11",{"date":284,"type":37},"2023-10-27",{"date":286,"type":21},"2027-10-15",{"name":288,"class":44},"University of California, San Francisco",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":296,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":22,"phases":299,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":45},"100502600","exercise-and-heart-transplant-100502600","NCT05824364","Exercise aNd hEArt Transplant","ENEA","Inclusion Criteria:\n\n* All the patients admitted in the on-site CR after HTx\n\nExclusion Criteria:\n\n* unable to sign informed consent",true,{"count":298,"type":21},40,[24],"Registry-based randomized clinical trial (RRCT) to assess the safety and efficacy of two different schemes of exercise training in patients who have recently undergone heart transplantation",[28],[32,303,304],"telerehabilitation","rehabilomics","2025-08-25",{"date":307,"type":37},"2025-09-02",{"date":309,"type":37},"2023-05-20",{"date":311,"type":21},"2025-11-28",{"name":313,"class":44},"Fondazione Don Carlo Gnocchi Onlus",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":322,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":45},"100588496","phase-4-optimize-immunosuppressive-therapy-using-everolimus-and-low-dose-calcineurin-inhibitors-in-heart-transplant-patients-in-korea-100588496","NCT06942156","Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","A Prospective, Multicenter, Open-Label, Randomized, Comparative, Phase 4 Trial to Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","OPTIMIZE-HTx","Inclusion Criteria:\n\n1. Over 19 years old\n2. Patients with stable heart transplant graft function at least 28\\~100 days post transplant.\n3. Patients who are appropriate for combination therapy with Everolimus and Calcineurin inhibitor (CNI) at the investigator's discretion\n\nExclusion Criteria:\n\n1. Recipients who have had a prior organ transplant, or who underwent a heart transplant with the simultaneous transplantation of another organ.\n2. Recipients of heart from ABO-incompatible donor\n3. Recipients of heart from the donor aged 70 or older","19 Years",{"count":324,"type":21},140,[163],"The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.",[28],[85,329],"Everolimus","2025-04-21",{"date":332,"type":37},"2025-04-24",{"date":334,"type":21},"2025-08-14",{"date":336,"type":21},"2030-12",{"name":338,"class":124},"Chong Kun Dang Pharmaceutical",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":22,"phases":349,"briefSummary":350,"conditions":351,"keywords":354,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":4},"100474536","heartcare-immuno-optimization-in-cardiac-allografts-mosaic-100474536","NCT05459181","HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)","Molecular Outcome Surveillance Using AlloSure and AlloMap Guided Immunomodulation in Cardiac Transplant","MOSAIC","Inclusion Criteria:\n\n1. Heart transplant recipients \\\u003C2 weeks post-transplant\n2. Patients aged 18 years or older\n3. Planned post-transplant maintenance immunosuppression regimen consisting of prednisolone, tacrolimus and mycophenolate\n4. Female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception during the trial and for 3 months thereafter\n5. Participant is willing and able to give informed consent for participation in the trial\n6. In the Investigator's opinion, is able and willing to comply with all trial requirements\n\nExclusion Criteria:\n\nThe participant may not enter the trial if ANY of the following apply:\n\n1. Multi-visceral transplant recipients\n2. Female participant who is pregnant, lactating or planning pregnancy during the trial\n3. Heart transplant recipients undergoing desensitization protocols prior to transplant based off high immunological risk profiles (determined by treating clinician)\n4. Chronic oral steroid use for any reason that cannot be tapered off and discontinued\n5. Planned post-transplant immunosuppression regimen utilizing cyclosporine, azathioprine, mTOR inhibitors, and\u002For co-stimulatory blockers\n6. Contraindication to having AlloSure or AlloMap testing\n7. Participant with life expectancy of less than 6 months or is inappropriate for immuno-optimization (including those patients at increased risk of primary disease recurrence w\u002F reduction in post-transplant immunosuppression)\n8. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial. This includes clinical events that would significantly impact post-transplant immunosuppression such as major infectious complications or significant rejection episodes within the first month post-transplant.\n9. Participants who are currently or have previously participated in another research trial involving an investigational immunological drug in the past 12 weeks\n10. Any condition that would preclude protocol biopsies\n\nRandomization Criteria (assessed at Week 4)\n\nThe participant may not proceed with randomization if ANY of the following apply at Week 4 post-transplant:\n\n1. Maintenance immunosuppression that includes cyclosporine, azathioprine, mTOR inhibitors, and\u002For co-stimulatory blockers\n2. Any episodes of biopsy-proven acute rejection (ACR ≥2R or AMR\\*)\n3. Abnormal molecular profile defined as AlloSure \\>0.2%\n4. Allograft dysfunction defined as LVEF \\\u003C45%\n5. eGFR \\\u003C30mL\u002Fmin\n6. Presence of DSA (persistence of any pre-transplant DSA or dnDSA) \\*AMR 1 (H+) with DSA\u002Fgraft dysfunction or AMR \\> 2",{"count":348,"type":21},930,[24],"This is an unblinded, randomized, controlled, two-arm interventional research study enrolling patients who are undergoing heart transplantation. The aim of the study is to determine whether patients at low risk of rejection can safely reduce the doses of their post-transplant immunosuppression medications using a combination of tests that include donor-specific antibodies (DSA), histology (looking at tissue from the donor heart), donor-derived cell-free DNA (AlloSure), and gene expression profiling (AlloMap). Eligible participants will be randomized in a 1:1 ratio into the HeartCare immune-optimization (intervention) arm or the corresponding observational (control) arm. AlloSure and AlloMap are the components of the HeartCare panel developed by CareDx.",[28,352,353],"Immunosuppression","Allograft",[355,356,357,358,359,360,361,362,363,364],"HeartCare","Allograft loss and survival","Calcineurin inhibitors","Chronic immunosuppression","Steroid avoidance","Donor-specific antibodies","Donor-derived cell-free DNA","AlloSure","AlloMap","Gene expression profiling","2024-10-21",{"date":367,"type":37},"2024-10-23",{"date":369,"type":21},"2025-12",{"date":371,"type":21},"2026-09",{"name":373,"class":124},"CareDx",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":382,"enrollmentInfo":383,"targetDuration":385,"studyType":222,"phases":4,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":45},"100550905","brazilian-clinical-registry-of-heart-transplantation-100550905","NCT06453148","Brazilian Clinical Registry of Heart Transplantation","Prospective Clinical Registry of Heart Transplant Patients in Brazil","HESTIA","Inclusion Criteria:\n\n* Patients over 18 years old;\n* Heart Transplantation within 30 days of both sexes;\n\nExclusion Criteria:\n\n* Refusal to provide consent for the study;\n* In the judgment of the local investigator, any difficulty accessing follow-up visits","75 Years",{"count":384,"type":21},730,"3 Years","Prospective cohort clinical study, registry-based, multicenter, national, with the consecutive inclusion of patients with a history of Heart Transplantation in Brazil. The clinical registry will involve the participation until 25 centers. Patients will be included up to 30 days after Heart Transplant surgery and will be followed for one year. Laboratory tests and clinical parameters wil be collected in two clinical visits (6mo and 12 mo). The outcomes evaluate will be the total hospitalizations and all-cause death. It is expected to include 730 patients with a 12-month follow-up from the day of the transplant surgery. The findings of the HESTIA Registry may guide the management of post-heart transplant patients, aiming at reducing morbidity and mortality within 12 months after heart transplant surgery.",[388,28],"Heart Transplant Failure and Rejection","2024-06-07",{"date":391,"type":37},"2024-06-11",{"date":393,"type":21},"2024-08-25",{"date":395,"type":21},"2027-08-25",{"name":397,"class":44},"Hospital Israelita Albert Einstein",{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":133,"enrollmentInfo":405,"targetDuration":407,"studyType":222,"phases":4,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":4},"100436724","multimodal-imaging-evaluation-and-prognostic-analysis-of-cardiac-allograft-vasculopathy-in-heart-transplantation-100436724","NCT04966988","Multimodal Imaging Evaluation and Prognostic Analysis of Cardiac Allograft Vasculopathy in Heart Transplantation","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Inclusion Criteria:\n\n• Heart transplantation after January 1st, 2015.\n\nExclusion Criteria:\n\n•Age \\\u003C 18 years at the time of transplantation; Died within 48 h; Heart-lung transplantation; Heart\u002Fkidney transplantation; Re-transplanted within 7 days after transplantation.",{"count":406,"type":21},1000,"10 Years","The aim is to (1) establish a system of multimodal imaging technology; (2) jointly apply multimodal imaging technology to diagnose of cardiac allograft vasculopathy of heart transplantation; (3) construct a multimodal imaging technology prediction model of adverse events, screening the best non-invasive imaging prediction indicators.",[28],"2021-07-16",{"date":412,"type":37},"2021-07-19",{"date":414,"type":21},"2021-08-01",{"date":416,"type":21},"2026-08-01",{"name":418,"class":44},"Xie Mingxing"]